The FDA's fast lane for national-priority drugs is still on the books. It has not been moving.
Reuters reported on Thursday that the agency has shelved the Commissioner's National Priority Voucher program, the pilot launched in 2025 to cut review times to one or two months for medicines tied to designated national priorities. The report rested on six sources and internal documents. No new vouchers have been awarded since Commissioner Marty Makary left in May, the political-appointee council that oversaw the program has gone dormant, and companies have been told that applications will remain open but will not advance.
An HHS spokesperson, Emily Hilliard, disputed the characterization. She said the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing to refine the framework. A former HHS assistant secretary, Rich Danker, told Reuters the program is quietly being phased out.
The program has not been formally terminated. Its machinery has stopped.
What the program promised
The Commissioner's National Priority Voucher was designed as a shortcut through the FDA's standard review, which for a new drug typically runs about ten months. A voucher would move a product into a one- or two-month lane if the commissioner decided it addressed a national priority. The program was part of a broader push to speed access to treatments the administration considered strategically important, and mental health was near the top of the list.
An executive order on April 18 directed HHS to accelerate access to treatments for serious mental illness. The order did not create the voucher program, which predated it, but it gave the program its clearest priority list. The order put psychedelic candidates at the front of that effort, including psilocybin for treatment-resistant depression and major depressive disorder and methylone for post-traumatic stress disorder. For advocates who have argued that federal review is the bottleneck between promising trial data and patient access, the voucher program looked like the answer.
The program was not the FDA's older priority review voucher, a tradable asset that entitles the holder to a six-month review and sells for large sums on a secondary market. The commissioner's voucher was a separate designation, awarded at the commissioner's discretion, that put a product on a much shorter clock. That distinction matters because it located the power to choose inside the agency's leadership rather than in a market for review credits.
The record is real
The program did produce results. According to Reuters, 22 drugs received vouchers and 12 were approved, five of them after Makary's departure. For several of those products, the review was shortened by eight months or more.
The two most recent approvals, Merck's Lipfendra and Revolution Medicines' Rasonque, were not vetted by the program's oversight council, according to the report. Lipfendra is the first oral PCSK9 inhibitor, a once-daily pill for lowering LDL cholesterol in a class that had been injectable-only. The site covered its approval in July, when it was the program's ninth approval. At least one voucher holder has not reached the market: Merck KGaA's Pergoveris remains unapproved, Reuters reported.
Those numbers cut both ways. Twelve approvals in about a year and a half is a substantial body of decisions for a pilot. It is also a small sample, and the speed came from a process that concentrated authority in a commissioner and a council of political appointees rather than the agency's career review divisions.
The machinery went quiet
Makary left the agency in May. The FDA has had no confirmed commissioner since. The executive council that reviewed voucher candidates and pushed their applications along has not met, according to internal documents cited in the report. FDA leadership has told sponsors that applications can still be filed but will not move forward.
No formal announcement accompanied the change. The Reuters account is the first detailed public description of it, and the agency's press office has not published a notice of termination or suspension.
The nine products still in the program have reverted to career scientists for oversight of their review timelines. That includes COMP360, Compass Pathways' psilocybin candidate for treatment-resistant depression, which completed its NDA submission this week; PSIL201, Usona Institute's psilocybin candidate for major depressive disorder; and TSND-201, Transcend Therapeutics' methylone candidate for post-traumatic stress disorder.
The difference between the two tracks is not cosmetic. A standard new drug application carries a ten-month review clock; a priority review, six months. The voucher lane was shorter than either, and it came with attention from an executive council that could convene reviewers and resolve disputes. Sponsors plan manufacturing, pricing, and launch spending around an expected action date, and a shift from weeks to months changes those plans.
For Compass, the immediate question is whether its NDA will be reviewed on the standard or the priority clock, with the program dormant and no voucher moving it to the front. Usona and Transcend are in the same position: their candidates sit inside a program whose leadership has not been replaced.
The practical effect is a slower clock and a more conventional process. Whether that is a restoration of normal order or the loss of a program that was working depends on which part of the record you weight.
The criticisms that outlasted the program
The voucher program drew objections from regulatory experts from the start. Critics said the commissioner could handpick favored drugs, that the oversight council's composition invited political influence, and that the compressed timetable left too little room for the kind of review that catches safety problems before approval. Those objections were about the design, not about any single approval, and the program's suspension does not resolve them.
Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, called it the worst of both worlds. Her argument, as the Psychiatric Times reported it, was that the program combined the risk of political interference with limited practical benefit, since many of the drugs might have qualified for other expedited pathways anyway. Peter Lurie, a former FDA executive, criticized the decision to cede review judgments to political appointees and said the program lacked transparency.
Transparency has become its own thread. FiercePharma reported that the agency also appears to have paused publishing complete response letters, the documents that explain why a drug was rejected. The agency briefly halted and then resumed the practice in July, and the latest pause has not been formally announced.
Complete response letters are the agency's written explanation when it declines to approve an application as filed. They are not approval documents, but they give investors, physicians, and competing developers a record of what the agency found insufficient, whether the problem was manufacturing, trial design, or missing safety data. Publishing them has been the agency's practice, on and off. That is a separate question from the voucher program, but it concerns the same kind of judgment: how much the public gets to see about decisions that shape which medicines reach patients. For investors, the practical result is less to read. A company whose application is rejected can describe its own version of events, but the agency's written account has no substitute, and its absence makes one rejection harder to compare with another.
Supporters of the program have a case too. The program's priority list included serious mental illness, a category where the standard review clock has long been criticized as an obstacle to access. Twelve approvals, several of them months ahead of schedule, are the kind of outcome the program's architects promised. The question is whether those gains justified a process that concentrated discretion at the top of the agency.
The vote that could decide it
The program's fate now runs through the Senate. The Health, Education, Labor, and Pensions Committee has scheduled a Nov. 18 vote on Heidi Overton's nomination to lead the FDA. Overton faced questions at her September hearing about the agency's independence, and the site covered that hearing when it happened. At that hearing she affirmed that every vaccine on the market is safe and effective, while declining to break with the president on the subject.
The committee vote is a gate, not the final step. A nomination that clears HELP still needs floor time in a chamber working through a lame-duck calendar, and the agency has been run by acting leadership since May. The question the vote answers is narrower than whether the voucher program survives: it decides whether the agency gets a confirmed leader in time to make that call.
Steven Grossman, a regulatory consultant, told BioSpace that controversial nominations rarely advance during a lame-duck session. If Overton loses, Sara Brenner could reportedly return as acting commissioner in 2027. A confirmed commissioner could restart the voucher program, rewrite it, or let it lapse. An acting commissioner might do none of those things.
Either way, the nine products inside the program are not waiting for a policy decision. Their reviews are proceeding under career staff rather than the voucher council, while the agency's leadership question remains open.
The evidence for the program's value is a list of approvals and a set of shortened timelines, not a controlled comparison. Voucher candidates were selected because the commissioner judged them national priorities, which makes it hard to separate the effect of the voucher from the effect of the selection. Some of the twelve might have been approved on the standard clock within months anyway. What the record does show is that the program could move products quickly when its leadership chose to, and that the machinery stopped when the leadership left.
The voucher program was built on a bet that speed and political priority could be separated from the ordinary review process without losing the safeguards that make the process credible. The bet is now suspended rather than settled. The drugs that entered the fast lane are moving at the speed of the slow lane, and the Senate vote will decide who gets to choose what comes next.
Primary sources
- Reuters, "Exclusive: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say," Nov. 12, 2026.
- Psychiatric Times, "FDA Shelves Fast-Track Drug Review Initiative," Nov. 12, 2026.
- BioSpace, "FDA's commissioner voucher program reportedly shuttered ahead of Senate vote on Overton," Nov. 12, 2026.
- FiercePharma, "FDA appears to pause controversial speedy review program, complete response letter disclosures," Nov. 12, 2026.
- US Food and Drug Administration, "FDA accelerates action on treatments for serious mental illness following Executive Order," April 24, 2026.